vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and TRICO BANCSHARES (TCBK). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $109.4M, roughly 1.5× TRICO BANCSHARES ). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 5.4%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Trico Bancshares is a U.S.-headquartered regional bank holding company operating Tri Counties Bank. It offers a full range of retail and commercial banking services including deposit products, mortgages, small business loans, and wealth management, primarily serving consumers and SMEs in Northern California.
ESPR vs TCBK — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $109.4M |
| Net Profit | — | $33.6M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 42.6% |
| Net Margin | — | 251.6% |
| Revenue YoY | 143.7% | 9.0% |
| Net Profit YoY | — | 15.8% |
| EPS (diluted) | $0.32 | $1.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $109.4M | ||
| Q3 25 | $87.3M | $107.6M | ||
| Q2 25 | $82.4M | $103.6M | ||
| Q1 25 | $65.0M | $98.6M | ||
| Q4 24 | $69.1M | $100.4M | ||
| Q3 24 | $51.6M | $99.1M | ||
| Q2 24 | $73.8M | $97.9M | ||
| Q1 24 | $137.7M | $98.5M |
| Q4 25 | — | $33.6M | ||
| Q3 25 | $-31.3M | $34.0M | ||
| Q2 25 | $-12.7M | $27.5M | ||
| Q1 25 | $-40.5M | $26.4M | ||
| Q4 24 | — | $29.0M | ||
| Q3 24 | $-29.5M | $29.1M | ||
| Q2 24 | $-61.9M | $29.0M | ||
| Q1 24 | $61.0M | $27.7M |
| Q4 25 | 50.6% | 42.6% | ||
| Q3 25 | -11.4% | 43.2% | ||
| Q2 25 | 8.6% | 36.5% | ||
| Q1 25 | -34.0% | 35.8% | ||
| Q4 24 | -6.4% | 38.7% | ||
| Q3 24 | -31.0% | 39.8% | ||
| Q2 24 | 3.5% | 40.0% | ||
| Q1 24 | 52.5% | 38.3% |
| Q4 25 | — | 251.6% | ||
| Q3 25 | -35.9% | 31.6% | ||
| Q2 25 | -15.4% | 26.6% | ||
| Q1 25 | -62.2% | 26.7% | ||
| Q4 24 | — | 221.4% | ||
| Q3 24 | -57.2% | 29.3% | ||
| Q2 24 | -83.9% | 29.7% | ||
| Q1 24 | 44.3% | 28.2% |
| Q4 25 | $0.32 | $1.02 | ||
| Q3 25 | $-0.16 | $1.04 | ||
| Q2 25 | $-0.06 | $0.84 | ||
| Q1 25 | $-0.21 | $0.80 | ||
| Q4 24 | $-0.14 | $0.88 | ||
| Q3 24 | $-0.15 | $0.88 | ||
| Q2 24 | $-0.33 | $0.87 | ||
| Q1 24 | $0.34 | $0.83 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $157.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $1.3B |
| Total Assets | $465.9M | $9.8B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $157.0M | ||
| Q3 25 | $92.4M | $298.8M | ||
| Q2 25 | $86.1M | $314.3M | ||
| Q1 25 | $114.6M | $308.3M | ||
| Q4 24 | $144.8M | $145.0M | ||
| Q3 24 | $144.7M | $320.1M | ||
| Q2 24 | $189.3M | $206.6M | ||
| Q1 24 | $226.6M | $82.8M |
| Q4 25 | $-302.0M | $1.3B | ||
| Q3 25 | $-451.4M | $1.3B | ||
| Q2 25 | $-433.5M | $1.3B | ||
| Q1 25 | $-426.2M | $1.3B | ||
| Q4 24 | $-388.7M | $1.2B | ||
| Q3 24 | $-370.2M | $1.2B | ||
| Q2 24 | $-344.2M | $1.2B | ||
| Q1 24 | $-294.3M | $1.2B |
| Q4 25 | $465.9M | $9.8B | ||
| Q3 25 | $364.0M | $9.9B | ||
| Q2 25 | $347.1M | $9.9B | ||
| Q1 25 | $324.0M | $9.8B | ||
| Q4 24 | $343.8M | $9.7B | ||
| Q3 24 | $314.1M | $9.8B | ||
| Q2 24 | $352.3M | $9.7B | ||
| Q1 24 | $373.1M | $9.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $133.3M |
| Free Cash FlowOCF − Capex | — | $127.9M |
| FCF MarginFCF / Revenue | — | 116.9% |
| Capex IntensityCapex / Revenue | 0.0% | 4.9% |
| Cash ConversionOCF / Net Profit | — | 3.96× |
| TTM Free Cash FlowTrailing 4 quarters | — | $222.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $133.3M | ||
| Q3 25 | $-4.3M | $45.1M | ||
| Q2 25 | $-31.4M | $29.2M | ||
| Q1 25 | $-22.6M | $24.5M | ||
| Q4 24 | $-35.0M | $109.7M | ||
| Q3 24 | $-35.3M | $28.6M | ||
| Q2 24 | $-7.2M | $31.8M | ||
| Q1 24 | $53.8M | $25.1M |
| Q4 25 | — | $127.9M | ||
| Q3 25 | — | $43.2M | ||
| Q2 25 | — | $28.2M | ||
| Q1 25 | — | $22.8M | ||
| Q4 24 | — | $105.2M | ||
| Q3 24 | $-35.5M | $27.3M | ||
| Q2 24 | $-7.3M | $30.8M | ||
| Q1 24 | $53.8M | $24.1M |
| Q4 25 | — | 116.9% | ||
| Q3 25 | — | 40.2% | ||
| Q2 25 | — | 27.2% | ||
| Q1 25 | — | 23.1% | ||
| Q4 24 | — | 104.8% | ||
| Q3 24 | -68.7% | 27.6% | ||
| Q2 24 | -9.9% | 31.5% | ||
| Q1 24 | 39.0% | 24.4% |
| Q4 25 | 0.0% | 4.9% | ||
| Q3 25 | 0.0% | 1.7% | ||
| Q2 25 | 0.0% | 1.0% | ||
| Q1 25 | 0.0% | 1.7% | ||
| Q4 24 | 0.0% | 4.5% | ||
| Q3 24 | 0.3% | 1.3% | ||
| Q2 24 | 0.1% | 1.0% | ||
| Q1 24 | 0.1% | 1.0% |
| Q4 25 | — | 3.96× | ||
| Q3 25 | — | 1.33× | ||
| Q2 25 | — | 1.06× | ||
| Q1 25 | — | 0.93× | ||
| Q4 24 | — | 3.78× | ||
| Q3 24 | — | 0.98× | ||
| Q2 24 | — | 1.10× | ||
| Q1 24 | 0.88× | 0.90× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
TCBK
Segment breakdown not available.
